|
WO2005082938A2
|
|
Anti-human tenascin monoclonal antibody
|
|
EP1165610A1
|
|
Peptide useful in treating multiple sclerosis and a pharmaceutical composition comprising the same
|
|
EP0958829A1
|
|
Use of a peptide compound in the treatment of systemic lupus erythematosus
|
|
EP0948345A1
|
|
Pharmaceutical composition containing an inhibitor of immunoglobulin-receptor interaction
|
|
US5932692A
|
|
Antigenic peptides
|
|
EP0752425A2
|
|
Peptide ligands for the constant region of immunoglobulins
|
|
ITMI960831D0
|
|
New immunoglobulin-binding peptide(s) - for use in affinity chromatography and immunoassay
|
|
ITMI951328D0
|
|
Multimer peptides
|
|
ITRM940042D0
|
|
Process for the production of transgenic tomato plants which are resistant to viral infections
|
|
EP0587541A1
|
|
Process to purify the big-endothelin protein
|
|
CA2137671A1
|
|
Mobile-module plant for the development and the production of biotechnological products on a pilot scale
|
|
WO9306489A1
|
|
Method to detect tumor necrosis factor (tnf) as bioactive form
|
|
EP0751225A1
|
|
Process for the identification of proteolytic activities and/or inhibitors thereof
|
|
EP0460569A1
|
|
Process for identifying polynucleotide sequences and device suitable therefor
|
|
ITRM910261D0
|
|
Procedure for the identification of proteolytic activity or proteolytic activity-inhibiting activity
|
|
IT9048365D0
|
|
Non-linearly covalently bonded peptides which are hydropathically complementary to known amino acid sequences and a process for their synthesis
|
|
EP0411503A1
|
|
Process for identifying and synthesizing binding sites of interacting proteins
|
